Loading...
•
Dec 31, 2021
Checkpoint Therapeutics Q4 2021 Earnings Report
Reported financial results for the full-year ended December 31, 2021 and recent corporate highlights.
Key Takeaways
Checkpoint Therapeutics announced its full-year 2021 financial results, highlighting a transformational period with the foundation laid for value-enhancing catalysts in 2022, including a planned BLA submission for cosibelimab.
Checkpoint Therapeutics is focused on developing novel treatments for solid tumor cancers.
The company is evaluating cosibelimab, a potential best-in-class anti-PD-L1 antibody, in a Phase 1 clinical trial.
Checkpoint intends to submit a Biologics License Application for cosibelimab in metastatic cSCC later in 2022.
Olafertinib is being evaluated as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Checkpoint Therapeutics
Checkpoint Therapeutics
Forward Guidance
Checkpoint Therapeutics anticipates multiple potentially value enhancing catalysts in 2022.
Positive Outlook
- Planned Biologics License Application submission for cosibelimab.
- Advancing pipeline of product candidates.
- Expanding patient access globally to potentially life-saving novel oncology therapies.
- Positive topline results from ongoing registrational trial of cosibelimab in metastatic cutaneous squamous cell carcinoma.
- Focus on expeditiously advancing product candidates.
Challenges Ahead
- Risk of delays in BLA submission.
- Potential for safety issues or trends observed in clinical trials.
- Risk that regulatory authorities may not accept application for approval.
- Dependence on third-party suppliers.
- Impact of evolving Russia/Ukraine conflict and COVID-19 pandemic.